close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDX
From The DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Aldeyra Therapeutics, Inc. Class Action
From Robbins LLP 
Via Business Wire
News headline image
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc. Investors – ALDX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
From Pomerantz LLP
Via GlobeNewswire
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX
From The Rosen Law Firm, P.A.
Via Business Wire
Top movers in Thursday's session ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Why Did ALDX Stock Tank 75% In Pre-Market Today? ↗
The U.S. FDA rejected Aldeyra’s application for a dry eye drug, citing a “lack of substantial evidence.” 
Via Stocktwits
News headline image
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Rise As Nvidia GTC, Iran Tensions, Fed Meet Loom: Why META, MU, SOC, ALDX Are Also In Focus Today ↗
Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait ↗
The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16. 
Via Stocktwits
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗
The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today